“减肥新药”卖爆，销售额同比增363%！小摩：2030年销售额将超千亿美元

格隆汇2023-09-11

减肥药概念股今日表现强劲，常山药业20cm涨停，金凯生科涨超11%，圣诺生物、昊帆生物、诺泰生物等纷纷冲高。近日司美格鲁肽（商品名：Wegovy）等减肥新药热卖引市场关注，丹麦制药巨头诺和诺德（novo nordisk）超越奢侈品巨头LVMH，成为欧洲市值最高的公司。礼来股价也连番大涨，目前市值已超5500亿美元，是辉瑞的两倍多。此外，摩根大通提高了对减肥药的销售额预测，预计到2030年这种GLP...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

星元未来
2024-03-02
星元未来
，

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2366366393?lang=zh_CN&edition=full","thumbnail":"https://img3.gelonghui.com/23bd7-b1ea8c62-e16c-47da-8c4f-414c06832007.jpg","is_english":false,"pubTime":"2023-09-11 12:28","share_image_url":"https://static.laohu8.com/6b8fa6424aebe95f6781d04ef17a1852","id":"2366366393","market":"us","top_or_hot":-1,"title":"“减肥新药”卖爆，销售额同比增363%！小摩：2030年销售额将超千亿美元","media":"格隆汇","content":"<div>\n<p>减肥药概念股今日表现强劲，常山药业20cm涨停，金凯生科涨超11%，圣诺生物、昊帆生物、诺泰生物等纷纷冲高。近日司美格鲁肽（商品名：Wegovy）等减肥新药热卖引市场关注，丹麦制药巨头诺和诺德（novo nordisk）超越奢侈品巨头LVMH，成为欧洲市值最高的公司。礼来股价也连番大涨，目前市值已超5500亿美元，是辉瑞的两倍多。此外，摩根大通提高了对减肥药的销售额预测，预计到2030年这种GLP...</p>\n\n<a href=\"https://www.gelonghui.com/p/643731\">网页链接</a>\n\n</div>\n","source":"gelonghui_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>“减肥新药”卖爆，销售额同比增363%！小摩：2030年销售额将超千亿美元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n“减肥新药”卖爆，销售额同比增363%！小摩：2030年销售额将超千亿美元\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-09-11 12:28 北京时间&nbsp;&nbsp;&nbsp;<a href=https://www.gelonghui.com/p/643731><strong>格隆汇</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>减肥药概念股今日表现强劲，常山药业20cm涨停，金凯生科涨超11%，圣诺生物、昊帆生物、诺泰生物等纷纷冲高。近日司美格鲁肽（商品名：Wegovy）等减肥新药热卖引市场关注，丹麦制药巨头诺和诺德（novo nordisk）超越奢侈品巨头LVMH，成为欧洲市值最高的公司。礼来股价也连番大涨，目前市值已超5500亿美元，是辉瑞的两倍多。此外，摩根大通提高了对减肥药的销售额预测，预计到2030年这种GLP...</p>\n\n<a href=\"https://www.gelonghui.com/p/643731\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0882574139.USD","symbol_name":"富达环球消费行业基金A ACC","start_time":0,"source_url":"https://www.gelonghui.com/p/643731","article_id":"2366366393","we_media_id":null,"thumbnails":["https://img3.gelonghui.com/23bd7-b1ea8c62-e16c-47da-8c4f-414c06832007.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2366366393","pubTimestamp":1694406491,"columns":[],"sourceInfo":{"source_id":"gelonghui_highlight","name":"格隆汇"},"weMediaInfo":null,"summary":"国内药企争相布局","collect":0,"end_time":0,"defaultTopTitle":"gelonghui.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"300255":"常山药业","301393":"昊帆生物","301509":"金凯生科","688076":"诺泰生物","688117":"圣诺生物","LU0882574139.USD":"富达环球消费行业基金A ACC","LU2552382132.HKD":"WELLINGTON US BRAND POWER \"A\" (HKD) ACC","LU1668664300.SGD":"Blackrock World Financials A2 SGD-H","LU1244550494.USD":"FRANKLIN GLOBAL MULTI-ASSET INCOME \"A\" (USDHEDGED) ACC","LU1496350171.SGD":"FRANKLIN DIVERSIFIED BALANCED \"A\" (SGDHDG) ACC","LU1496350502.SGD":"FRANKLIN DIVERSIFIED DYNAMIC \"A\" (SGDHDG) ACC","LU0211328371.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (MDIS) (USD)   INC","BK0229":"化学制品","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","BK4550":"红杉资本持仓","BK0188":"融资融券","IE00B775SV38.USD":"NEUBERGER BERMAN US MULTICAP OPPORTUNITIES \"A\" (USD) ACC","000963":"华东医药","BK0187":"一线龙头","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","BK4207":"综合性银行","BK1161":"生物科技","BK4566":"资本集团","BK0175":"白马股","LU1162221912.USD":"FRANKLIN INCOME \"A\" (USD) ACC","LU2552382058.USD":"WELLINGTON US BRAND POWER \"A\" (USD) ACC","SG9999002232.USD":"Allianz Global High Payout USD","BK0196":"行业龙头","LU0310799852.SGD":"FTIF - Templeton Global Equity Income A MDIS SGD","LU1670627923.USD":"M&G (LUX) NORTH AMERICAN DIVIDEND \"A\" (USD) ACC","SG9999002224.SGD":"Allianz Global High Payout SGD","LU1363072403.SGD":"Fidelity Global Financial Services A-ACC-SGD","01801":"信达生物","BK0132":"高送转概念","LU0320765489.SGD":"FTIF - Franklin Mutual US Value A Acc SGD","NVO":"诺和诺德","JPM":"摩根大通","LU0496365809.HKD":"TEMPLETON GLOBAL INCOME \"A\" (HKD) INC (Q)","LU0070302665.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) ACC","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","BK1589":"北水核心资产","BK4585":"ETF&股票定投概念","LU0971096721.USD":"富达环球金融服务 A","LU1244550221.USD":"FRANKLIN GLOBAL MULTI-ASSET  INCOME \"A\" (USDHEDGED) INC (M)","LU2552382215.SGD":"WELLINGTON US BRAND POWER \"A\" (SGDHDG) ACC","BK4007":"制药","LU0976567544.SGD":"FTIF - Templeton Global Income A Mdis SGD-H1","LU1267930490.SGD":"TEMPLETON GLOBAL EQUITY INCOME \"AS\" (SGD) INC A","LU0149725797.USD":"汇丰美国股市经济规模基金","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD"},"translate_title":"The sales of \"new slimming drugs\" exploded, and the sales increased by 363% year-on-year! Xiaomo: Sales will exceed 100 billion US dollars in 2030","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"300255":0.9,"301393":0.9,"301509":0.9,"688076":0.9,"688117":0.9,"JPM":1,"01801":0.9,"NVO":0.9,"000963":0.9},"content_text":"减肥药概念股今日表现强劲，常山药业20cm涨停，金凯生科涨超11%，圣诺生物、昊帆生物、诺泰生物等纷纷冲高。近日司美格鲁肽（商品名：Wegovy）等减肥新药热卖引市场关注，丹麦制药巨头诺和诺德（novo nordisk）超越奢侈品巨头LVMH，成为欧洲市值最高的公司。礼来股价也连番大涨，目前市值已超5500亿美元，是辉瑞的两倍多。此外，摩根大通提高了对减肥药的销售额预测，预计到2030年这种GLP-1激动剂类药物的年销售额将超过1000亿美元，诺和诺德、礼来总市值不断刷创新高。中信证券测算，2030年中国减肥用GLP-1受体激动剂的市场规模将达到383亿元。“减肥新药”卖爆2023H1销售额同比增长363%2023年8月3日，Science杂志在线发表一篇题为“Turning the tide on obesity”的社论性文章，文中指出：全球现下有超过十亿人患有肥胖症，超重的比例甚至更多。随着新型高效减重药物的出现，科学家们正翘首以盼这类药物能否让“肥胖时代”的流行画上历史性的句号。世界肥胖联盟在2023年3月公布了最新版《世界肥胖地图》报告，“预计2035年，全球将有超过40亿人超重/肥胖，占全球总人口的一半以上”。另外一份数据显示，帕博利珠单抗全球销售额超120亿美元，首次问鼎“药王”宝座；降糖“新宠”司美格鲁肽销售额暴涨363%，一举迈入榜单前三。2023上半年全球畅销药品TOP10资料显示，司美格鲁肽由诺和诺德研发，是一款同时获批肥胖和2型糖尿病双适应症的GLP-1激动剂。该药自2017年全球首次上市后，不到6年时间便跻身2023H1全球畅销药TOP3行列。目前司美格鲁肽共有3款产品获批在售，分别为Ozempic（注射用降糖药）、Rybelsus（口服降糖药）、Wegovy（注射用减重药），得益于Wegovy销售额的突飞猛进，2023H1同比增长363%，2023上半年已突破90亿美元。国内多家药企公布GLP-1类药品研发进展6月3日，丹麦药企诺和诺德生产的司美格鲁肽注射液，对肥胖患者的适应症扩容正式获得国家药监局受理。在接下来一年内，该药物可能在国内获批上市。据粗略统计，目前国内最少有25家企业，选择以减重为管线进行着GLP-1类药物的研发。目前，我国唯一获批的GLP-1类减肥药，只有华东医药于今年7月份获批的利拉鲁肽注射液。司美格鲁肽国内进入3期的有齐鲁，华东，联邦，丽珠医药。信达生物IBI362（GLP-1R/GCGR 双靶点）目前处于临床3期阶段，恒瑞医药HRS953（GLP-1R/GIPR）临床2期中。小摩预测2030年年销售额将超1000亿美元摩根大通分析师Chris Schott表示，他不排除GLP-1在肥胖和糖尿病领域的销售额进一步上升的可能性，在社交媒体的大肆宣传下，这类药物的使用量正在迅速上升。该行预计到2030年这种GLP-1激动剂类药物的年销售额将超过1000亿美元，诺和诺德和礼来形成双寡头垄断。高盛在报告中指出，肥胖每年给美国的医疗系统带来1700亿美元的成本，而到2035年，这种慢性疾病的影响将使全球GDP减少4万亿美元，相当于全球第四大经济体德国2022年的GDP，而以GLP-1类疗法为主的减肥药有望给这一趋势带来革命新的改变。该行表示，减肥药物市场将从今年的刚刚超过50亿美元扩大到2030年的440亿美元，翻了近9倍，而这种增长将使诺和诺德和礼来的减肥药大幅受益。高盛投资组合经理Jenny Chang表示，减肥药物市场“历史上一直受限”，而随着监管给更更多此类新药“亮绿灯”，使得这批有前景的新药完全可以进入市场。财通证券指出，相比于传统降糖、减重药物，GLP-1类药物兼具有效性高、安全性佳的优点，近年来利拉鲁肽、司美格鲁肽、替尔泊肽等品种相继上市，可以预计随着推动市场教育进一步加快，将促进GLP-1类药物在降糖、减重人群中渗透率不断提升。","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":279796308074616,"gmtCreate":1709331062713,"gmtModify":1709334215160,"author":{"id":"4097226743085970","authorId":"4097226743085970","name":"星元未来","avatar":"https://static.tigerbbs.com/3a8e915d7f808030bbf9731d84347a96","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4097226743085970","authorIdStr":"4097226743085970"},"htmlText":"，","listText":"，","text":"，","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/279796308074616","repostId":2366366393,"repostType":2,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":0,"commentSize":1,"repostSize":1,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.4","shortVersion":"4.29.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2366366393"}